Home Newsfeeds Oppenheimer Maintains Outperform on Focus Finl Partners, Lowers Price Target to $52

Oppenheimer Maintains Outperform on Focus Finl Partners, Lowers Price Target to $52

Oppenheimer analyst Owen Lau maintains Focus Finl Partners (NASDAQ:FOCS) with a Outperform and lowers the price target from $60 to $52.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Oppenheimer analyst Owen Lau maintains Focus Finl Partners (NASDAQ:FOCS) with a Outperform and lowers the price target from $60 to $52.

Abeona Therapeutics Provides Regulatory Update On Pz-cel; CRL Did Not Identify Deficiencies Related To Clinical Efficacy Or Clinical Safety Data In BLA, And No New Clinical Studies Requested By FDA To Support Approval

By Benzinga Newsdesk

April 22, 4:06 PM

Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies

ABEO

Elon Musk’s Favourite Coin’s Future, Israel-Hamas War Impact And More: This Week In Crypto

By Benzinga Neuro

October 14, 8:15 PM

The week was filled with numerous stories that continued to shape the rapidly evolving landscape of the cryptocurrency market. From predictions of a potential plunge in Dogecoin’s value to the Israel-Hamas conflict’s impact on the crypto markets, the weekend was anything but quiet. The following round-up provides a quick snapshot of the key stories.

$DOGE